Clinical Trial Update: Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in HIV-infected adults previously immunized with the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Pneumococcal Infection

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)
• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: HIV Infections, Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2013-06-10